



Updated: 05/2019  
DMMA Approved: 05/2019

**Request for Prior Authorization for Visudyne (verteporfrin)**  
**Website Form – [www.highmarkhealthoptions.com](http://www.highmarkhealthoptions.com)**  
**Submit request via: Fax - 1-855-476-4158**

All requests for Visudyne (verteporfrin) require a Prior Authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

**Visudyne (verteporfrin) Prior Authorization Criteria:**

For all requests for Visudyne (verteporfrin) all of the following criteria must be met:

- The member is 18 years of age or older
- The treatment is prescribed by, or in consultation with, an ophthalmologist
- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines

Coverage may be provided with a diagnosis of Age Related Macular Degeneration and the following criteria is met:

- The member has had a trial and failure of a vascular endothelial growth factor (VEGF) inhibitor (e.g. Avastin), or submitted a clinical reason for not having a trial of a vascular endothelial growth factor (VEGF) inhibitor (e.g. Avastin)

Coverage may be provided with a diagnosis of Subfoveal Choroidal Neovascularization and the following criteria is met:

- Must provide documentation showing neovascularization is due to pathologic myopia, or presumed ocular histoplasmosis

**Initial Duration of Approval:** 12 months

**Reauthorization criteria**

- Member continues to meet initial criteria for medical necessity

**Reauthorization Duration of Approval:** 12 months

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.

**VISUDYNE (VERTEPORFRIN)  
PRIOR AUTHORIZATION FORM**

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Highmark Health Options Pharmacy Services. **FAX:** (855) 476-4158

If needed, you may call to speak to a Pharmacy Services Representative.

**PHONE:** (844) 325-6253 Monday through Friday 8:30am to 5:00pm

**PROVIDER INFORMATION**

|                      |                 |
|----------------------|-----------------|
| Requesting Provider: | NPI:            |
| Provider Specialty:  | Office Contact: |
| Office Address:      | Office Phone:   |
|                      | Office Fax:     |

**MEMBER INFORMATION**

|                    |   |
|--------------------|---|
| Member Name:       | DOB:                                    |
| Health Options ID: | Member weight: _____ pounds or _____ kg |

**REQUESTED DRUG INFORMATION**

|  |           |
|--|-----------|
| Medication:  | Strength: |
| Frequency:   | Duration: |
| Is the member currently receiving requested medication? <input type="checkbox"/> Yes <input type="checkbox"/> No   |           |
| Date Medication Initiated:   |           |
| Is this medication being used for a chronic or long-term condition for which the medication may be necessary for the life of the patient? <input type="checkbox"/> Yes <input type="checkbox"/> No |           |

**Billing Information**

|  |  |
|--|--|
| This medication will be billed: <input type="checkbox"/> at a pharmacy <b>OR</b><br><input type="checkbox"/> medically (if medically please provide a JCODE: _____)  |  |
| Place of Service: <input type="checkbox"/> Hospital <input type="checkbox"/> Provider's office <input type="checkbox"/> Member's home <input type="checkbox"/> Other |  |

**Place of Service Information**

|          |        |
|----------|--------|
| Name:    | NPI:   |
| Address: | Phone: |
|          |        |

**MEDICAL HISTORY (Complete for ALL requests)**

Diagnosis: ICD-10 \_\_\_\_\_

Age Related Macular Degeneration:  
Has the member tried and failed a VEGF inhibitor (e.g. Avastin) or is there a clinical reason for not having a trial of a VEGF inhibitor? ☐ Yes ☐ No

Subfoveal Choroidal Neovascularization:  
Is the neovascularization due to pathologic myopia or presumed ocular histoplasmosis? ☐ Yes ☐ No

**CURRENT or PREVIOUS THERAPY**

| Medication Name | Strength/ Frequency | Dates of Therapy | Status (Discontinued & Why/Current) |
|-----------------|---------------------|------------------|-------------------------------------|
|                 |                     |                  |                                     |
|                 |                     |                  |                                     |
|                 |                     |                  |                                     |

**SUPPORTING INFORMATION or CLINICAL RATIONALE**

|  |
|--|
|  |
|  |
|  |
|  |

|                                |      |
|--------------------------------|------|
| Prescribing Provider Signature | Date |
|                                |      |

